Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PRTG Stock Summary
Top 10 Correlated ETFs
PRTG
In the News

New Strong Buy Stocks for January 26th
FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

New Strong Buy Stocks for January 20th
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

New Strong Buy Stocks for November 1st
FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.

Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?
The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform
Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired.

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference
WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. Dr. Walters will give an overview of Portage's pipeline and status of current programs, including the company's lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

Portage Biotech Announces Participation in September 2021 Investor Conferences
WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021.

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
- $29 million raised during quarter with broad institutional support

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors.

Portage Biotech Added to Russell 2000(R) Index
Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to the Russell 2000 Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opened on June 28. "Inclusion in the Russell 2000 index marks another key milestone for Portage,...
PRTG Financial details
PRTG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 46.21 | -0.55 | -0.49 | -1.35 | -1.29 | |
Operating cash flow per share | -0.4 | -0.18 | -0.34 | -0.37 | -0.52 | |
Free cash flow per share | -0.4 | -0.18 | -0.34 | -0.37 | -0.52 | |
Cash per share | 2.83 | 1.3 | 0.29 | 0.24 | 1.79 | |
Book value per share | 3.59 | 20.68 | 8.81 | 8.65 | 9.28 | |
Tangible book value per share | 3.59 | -2.52 | -1.38 | -1.12 | 0.36 | |
Share holders equity per share | 3.59 | 20.68 | 8.81 | 8.65 | 9.28 | |
Interest debt per share | 0.1 | 0.78 | 0.39 | 0.17 | 0 | |
Market cap | 20.08M | 45.31M | 99.66M | 328.17M | 85.8M | |
Enterprise value | 12.8M | 42.8M | 100.17M | 327.2M | 62.45M | |
P/E ratio | 0.16 | -17.19 | -18.69 | -20.73 | -5.09 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -18.72 | -52.81 | -26.83 | -76.6 | -12.69 | |
PFCF ratio | -18.72 | -52.81 | -26.83 | -76.6 | -12.69 | |
P/B Ratio | 2.09 | 0.45 | 1.03 | 3.23 | 0.71 | |
PTB ratio | 2.09 | 0.45 | 1.03 | 3.23 | 0.71 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.1 | -16.81 | -38.36 | -24.49 | -5.01 | |
EV to operating cash flow | -11.93 | -49.89 | -26.97 | -76.38 | -9.23 | |
EV to free cash flow | -11.93 | -49.89 | -26.97 | -76.38 | -9.23 | |
Earnings yield | 6.16 | -0.06 | -0.05 | -0.05 | -0.2 | |
Free cash flow yield | -0.05 | -0.02 | -0.04 | -0.01 | -0.08 | |
Debt to equity | 0.04 | 0.25 | 0.29 | 0.27 | 0.24 | |
Debt to assets | 0.04 | 0.14 | 0.16 | 0.16 | 0.15 | |
Net debt to EBITDA | -0.06 | 0.98 | -0.19 | 0.07 | 1.87 | |
Current ratio | 59.97 | 3.65 | 1.48 | 1.54 | 31.71 | |
Interest coverage | -69.59 | -31.41 | -10.73 | -70.28 | -362.51 | |
Income quality | -0.01 | 0.33 | 0.7 | 0.27 | 0.35 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.93 | 0.93 | 0.92 | 0.83 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 61.11 | 15.95 | 9.83 | 16.2 | 16.42 | |
ROIC | 0.43 | -0.02 | -0.05 | -0.08 | -0.14 | |
Return on tangible assets | 12.37 | -0.2 | -0.43 | -1.12 | -0.5 | |
Graham Net | 2.69 | -3.91 | -2.22 | -2.04 | -0.44 | |
Working capital | 7.49M | 4.76M | 1.23M | 1.74M | 24.05M | |
Tangible asset value | 9.62M | -12.16M | -15.07M | -13.11M | 4.72M | |
Net current asset value | 7.23M | -18.61M | -23.74M | -22.31M | -4.4M | |
Invested capital | 0.02 | 0.04 | 0.04 | 0.02 | 0 | |
Average receivables | 22.22K | 41.5K | 57.5K | 371.5K | 446K | |
Average payables | 118.03K | 257.5K | 365.5K | 228K | 150.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 12.86 | -0.03 | -0.06 | -0.16 | -0.14 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.22 | -0.26 | -0.13 | -0.06 | -0.44 | |
Operating cash flow per share | -0.1 | -0.12 | -0.16 | -0.15 | -0.16 | |
Free cash flow per share | -0.1 | -0.12 | -0.16 | -0.15 | -0.16 | |
Cash per share | 2.04 | 1.92 | 1.59 | 0.9 | 0.77 | |
Book value per share | 9.54 | 9.43 | 9.04 | 10.66 | 9.92 | |
Tangible book value per share | 0.97 | 0.81 | 0.32 | -0.7 | -1.24 | |
Share holders equity per share | 9.54 | 9.43 | 9.04 | 10.66 | 9.92 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 270.91M | 143.18M | 93.19M | 114.18M | 90.12M | |
Enterprise value | 243.65M | 117.58M | 72.01M | 99.14M | 77.02M | |
P/E ratio | -22.77 | -10.19 | -13.47 | -30.08 | -3.01 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -212.48 | -86.36 | -42.83 | -45.45 | -33.33 | |
PFCF ratio | -212.48 | -86.36 | -42.83 | -45.4 | -33.33 | |
P/B Ratio | 2.13 | 1.14 | 0.77 | 0.64 | 0.53 | |
PTB ratio | 2.13 | 1.14 | 0.77 | 0.64 | 0.53 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -70.19 | -34.64 | -16.9 | -28.38 | -14.71 | |
EV to operating cash flow | -191.09 | -70.92 | -33.09 | -39.47 | -28.48 | |
EV to free cash flow | -191.09 | -70.92 | -33.09 | -39.42 | -28.48 | |
Earnings yield | -0.01 | -0.02 | -0.02 | -0.01 | -0.08 | |
Free cash flow yield | 0 | -0.01 | -0.02 | -0.02 | -0.03 | |
Debt to equity | 0.2 | 0.19 | 0.23 | 0.22 | 0.25 | |
Debt to assets | 0.13 | 0.12 | 0.14 | 0.18 | 0.2 | |
Net debt to EBITDA | 7.85 | 7.54 | 4.97 | 4.31 | 2.5 | |
Current ratio | 21.31 | 41.31 | 11.73 | 11.98 | 6.41 | |
Interest coverage | -475.71 | -4.17K | -194.62 | -405.89 | -95.18 | |
Income quality | 0.43 | 0.47 | 1.34 | 2.32 | 0.36 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.81 | 0.82 | 0.83 | 0.87 | 0.9 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.92 | 7.47 | 5.13 | 3.69 | 9.9 | |
ROIC | -0.02 | -0.03 | -0.01 | -0.01 | -0.04 | |
Return on tangible assets | -0.08 | -0.1 | -0.05 | -0.04 | -0.35 | |
Graham Net | 0.22 | 0.1 | -0.49 | -1.38 | -1.68 | |
Working capital | 27.3M | 25.64M | 21.14M | 15.74M | 13.11M | |
Tangible asset value | 12.87M | 10.85M | 4.3M | -11.64M | -21.15M | |
Net current asset value | 3.79M | 2.03M | -4.76M | -21.55M | -26.85M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 816K | 374.5K | 0 | 545.5K | 832K | |
Average payables | 802.5K | 238.5K | 0 | 1.68M | 1.92M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.02 | -0.03 | -0.01 | -0.01 | -0.04 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
PRTG Frequently Asked Questions
What is Portage Biotech Inc. stock symbol ?
Portage Biotech Inc. is a VG stock and trading under the symbol PRTG
Is Portage Biotech Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $19.5. The lowest prediction is $18 and the highest is $21
What is PRTG stock prediction ?
What is Portage Biotech Inc. stock quote today ?
Portage Biotech Inc. stock price is $3.09 today.
Is Portage Biotech Inc. stock public?
Yes, Portage Biotech Inc. is a publicly traded company.